Intensity Therapeutics is like a specialized biotech that uses a novel delivery system to inject common chemotherapy drugs directly into tumors, effectively creating an "in-tumor vaccine" that aims to activate the body's immune system systemically, similar to the goal of immunotherapies like Merck's Keytruda.

• INT230-6: A lead investigational drug candidate for direct intratumoral injection, combining cisplatin and vinblastine sulfate with an amphiphilic molecule to kill tumor cells and activate a systemic immune response in various cancers.

Intensity Therapeutics (INTS) is a clinical-stage biotechnology company. As such, its product candidate, INT230-6, is currently undergoing clinical trials and has not yet received regulatory approval for commercial sale. Therefore, the company does not have major commercial customers, whether other companies or individuals, for its drug product at this time.

The company is focused on the research and development of its drug candidates and conducting clinical trials to gather safety and efficacy data for eventual market approval.

Lewis H. Bender, MS, MA, MBA – Chairman of the Board, President and CEO

Lewis H. Bender is the founder of Intensity Therapeutics, Inc. and has served as its President and Chief Executive Officer since April 2012. Prior to founding Intensity Therapeutics, he served as the CEO of Interleukin Genetics, Inc., a publicly traded personalized medicine company, from 2008 to 2012. At Interleukin Genetics, Mr. Bender successfully restructured the company, increased sales, developed a new genetic-based testing platform, and partnered with a major insurance provider. Before Interleukin Genetics, he held various positions at Emisphere Technologies, Inc., a publicly traded drug delivery company, including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. He has over 28 years of biopharmaceutical leadership experience and has led teams in developing products from discovery to Phase 3 using novel drug delivery techniques. Mr. Bender has also partnered with several major pharmaceutical and biotech companies.

Joseph Talamo, CPA – Chief Financial Officer

Joseph Talamo joined Intensity Therapeutics as Chief Financial Officer in December 2023. He brings over 25 years of experience in financial leadership roles within biopharmaceutical companies. Most recently, Mr. Talamo was the Senior Vice President and Chief Financial Officer of HiberCell, Inc., a clinical-stage biotechnology company, from 2020 to 2023. Before HiberCell, he spent ten years at Caladrius Biosciences, Inc., a publicly-traded clinical-stage biopharmaceutical company, where he served as Senior Vice President and Chief Financial Officer from 2015 to 2020. From 1996 to 2010, Mr. Talamo held various senior positions, including Vice President and Corporate Controller, at OSI Pharmaceuticals, Inc., another publicly-traded biopharmaceutical company.

John Wesolowski, CPA, MBA – Principal Accounting Officer and Controller

John Wesolowski has served as Intensity Therapeutics' Principal Accounting Officer and Controller since March 2017. He also held the role of Interim Chief Financial Officer from June 2023 until December 2023. Prior to joining Intensity Therapeutics, Mr. Wesolowski was the Director of Costing in the Yale University Controller's office from 1998 to 2016, where he managed financial reporting, property tax, and overhead/benefit rate calculations.

Kimberly A. Guedes, RN, MBA – Vice President of Clinical Operations

Kimberly A. Guedes serves as the Vice President of Clinical Operations at Intensity Therapeutics.

Doranne Frano – Regulatory Affairs and Quality Control

Doranne Frano is responsible for Regulatory Affairs and Quality Control at Intensity Therapeutics. She is a global life science regulatory, clinical, and quality professional with over 40 years of experience in pharmaceuticals, biotechnology, medical devices, diagnostics, and regulatory compliance. Her career began in Clinical Research at G.D. Searle, and she has held executive regulatory and quality roles, as well as provided consulting services to various pharmaceutical companies.

The key risks for Intensity Therapeutics (INTS) are:

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biotechnology company, Intensity Therapeutics' entire business model and future success are dependent on the successful completion of clinical trials for its lead product candidate, INT230-6, and subsequently obtaining regulatory approvals from agencies such as the FDA and Health Canada. The company is currently conducting Phase 2 trials (IT-01 and INVINCIBLE studies), and there is no guarantee that these trials will demonstrate sufficient safety and efficacy to advance to later stages or achieve regulatory approval. Failure at any stage of clinical development or inability to secure necessary approvals would significantly impact the company's viability. The background information mentions that 12% of patients in study IT-01 experienced Grade 3 treatment-related adverse events, highlighting the inherent risks and challenges in clinical development.

2. Intellectual Property Protection Risk: Intensity Therapeutics' competitive advantage stems from its patented and patent-pending anti-cancer product candidates, which involve novel formulations combining generic active anti-cancer agents (cisplatin and vinblastine sulfate) with amphiphilic molecules (SHAO). The effectiveness and market exclusivity of INT230-6 heavily rely on the strength and enforceability of these patents. Any challenges to their intellectual property, expiration of patent protection, or inability to secure additional patents for future innovations could allow competitors to replicate their approach, thereby diminishing their market position and revenue potential, especially since the active therapeutic agents themselves are generic.

Expected Drivers of Future Revenue Growth for Intensity Therapeutics (INTS)

Over the next 2-3 years, Intensity Therapeutics' (INTS) revenue growth will primarily be driven by key advancements in its clinical development and potential strategic collaborations, rather than direct product sales, given its clinical-stage nature. The expected drivers include:

1. Advancement and positive clinical trial data from the IT-01 study in refractory or metastatic cancers: The ongoing Phase 2 portion of the IT-01 study, particularly the expansion cohorts combining INT230-6 with Merck’s Keytruda® and Bristol-Myers Squibb’s Yervoy®, is a crucial driver. Positive safety and efficacy data from these trials, especially demonstrating strong systemic immune activation (abscopal effect), could significantly enhance the value of INT230-6 and potentially lead to pivotal trials, accelerated regulatory pathways, or attract substantial collaboration and licensing opportunities.
2. Successful progression and positive results from the INVINCIBLE study in early-stage breast cancer: The Phase 2 INVINCIBLE study evaluating INT230-6 as a pre-surgical treatment for early-stage breast cancer represents a significant potential market expansion. Favorable outcomes from this study could open up a new therapeutic indication and patient population for INT230-6, further broadening its commercial appeal and increasing its attractiveness for potential partners or direct market entry in the future.
3. Formation of strategic partnerships or licensing agreements for INT230-6: As a clinical-stage biotechnology company, a primary source of future revenue growth for Intensity Therapeutics will likely come from securing lucrative strategic partnerships or licensing agreements with larger pharmaceutical companies. Positive data from their ongoing clinical trials (IT-01 and INVINCIBLE) would be instrumental in attracting such collaborations, which could involve upfront payments, milestone payments based on clinical and regulatory achievements, and future royalties on sales, providing significant non-dilutive funding and validation for the company's platform.
4. Differentiation through its unique DfuseRx℠ discovery platform and mechanism of action: The company's patented DfuseRx℠ platform and the unique amphiphilic formulation of INT230-6, which aims to overcome challenges with tumor absorption of water-based products, represent a key differentiator. Continued evidence of INT230-6's ability to widely disperse, penetrate tumor cells, induce tumor cell death, and elicit a systemic anti-tumor immune response, including the abscopal effect, will enhance the perceived value and market potential of their product candidates, making them more attractive for investment and partnership deals that can drive future revenue.

Share Issuance

• Intensity Therapeutics raised over $20 million in gross proceeds during 2025 through two public offerings, one registered direct offering, and At-the-Market (ATM) issuances.
• In July 2025, the company secured $6.6 million in gross proceeds ($6.3 million net) by selling 19,868,658 shares of its common stock through an ATM offering at an average price of $0.3323 per share.
• An October 2025 registered direct offering brought in approximately $4 million in gross proceeds from a new long-term fundamental investor, with 5,000,000 shares of common stock sold at $0.80 per share.

Inbound Investments

• The company received approximately $4 million in gross proceeds from a registered direct offering to a new long-term fundamental investor in October 2025.
• Since the beginning of the second quarter of 2025, Intensity Therapeutics raised an aggregate of $11.3 million, with net proceeds of about $10.1 million, via public and At-the-Market offerings.

Capital Expenditures

• Intensity Therapeutics reported $0.0 in capital expenditures for the fiscal years ended December 31, 2020, 2021, 2022, 2023, and 2024.